Discontinuation of empirical antifungal therapy in ICU patients using 1,3-beta-D-glucan

dc.contributor.authorNucci, Marcio
dc.contributor.authorNouer, Simone A.
dc.contributor.authorEsteves, Patricia [UNIFESP]
dc.contributor.authorGuimaraes, Thais
dc.contributor.authorBreda, Giovanni
dc.contributor.authorde Miranda, Bianca Grassi
dc.contributor.authorQueiroz-Telles, Flavio
dc.contributor.authorColombo, Arnaldo L. [UNIFESP]
dc.date.accessioned2019-07-22T15:46:47Z
dc.date.available2019-07-22T15:46:47Z
dc.date.issued2016
dc.description.abstractEmpirical antifungal therapy in high-risk ICU patients is an attractive strategy, but overuse of antifungal agents is a potential problem. We evaluated if ICU patients at high risk to develop candidaemia identified by a prediction rule could discontinue empirical antifungal therapy on the basis of repeatedly negative 1-3-beta-d-glucan (BDG) tests. We conducted a multicentre cohort study in 85 ICU patients receiving antibiotics or with central venous catheter plus two additional factors (dialysis, parenteral nutrition, surgery, pancreatitis or receipt of corticosteroids or other immunosuppressive agents) plus either fever, hypothermia, hypotension, acidosis, elevated C-reactive protein or leucocytosis. Blood cultures (days 1 and 2) and BDG (days 1-3, baseline period) were performed and anidulafungin was given. On day 4, patients with negative blood cultures and BDG discontinued antifungal therapy. Registered in ClinicalTrials.gov (NCT01734525). The incidence of candidaemia was 8.2% in patients selected versus 0.5% in patients without entry criteria (16.9 times higher). Sixty-four patients (75.3%) had baseline positive BDG, including 7 with candidaemia. All 21 patients with baseline negative BDG discontinued anidulafungin on day 4. None developed candidaemia until day 30. Early discontinuation of empirical echinocandin therapy in high-risk ICU patients based on consecutive negative BDG tests may be a reasonable strategy, with great potential to reduce the overuse of echinocandins in ICU patients. Prospective studies with a higher number of patients are needed.en
dc.description.affiliationUniv Fed Rio de Janeiro, Univ Hosp, Rio De Janeiro, Brazil
dc.description.affiliationUniv Fed Sao Paulo, Univ Hosp, Sao Paulo, Brazil
dc.description.affiliationHosp Servidor Publ Sao Paulo, Sao Paulo, Brazil
dc.description.affiliationUniv Fed Parana, Univ Hosp, Curitiba, Parana, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo, Univ Hosp, Sao Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipPfizer
dc.format.extent2628-2633
dc.identifierhttp://dx.doi.org/10.1093/jac/dkw188
dc.identifier.citationJournal Of Antimicrobial Chemotherapy. Oxford, v. 71, n. 9, p. 2628-2633, 2016.
dc.identifier.doi10.1093/jac/dkw188
dc.identifier.issn0305-7453
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/51088
dc.identifier.wosWOS:000383911600037
dc.language.isoeng
dc.publisherOxford Univ Press
dc.rightsAcesso restrito
dc.titleDiscontinuation of empirical antifungal therapy in ICU patients using 1,3-beta-D-glucanen
dc.typeArtigo
Arquivos